MTOR and acute lymphoblastic leukemia: We observed a downregulation of the downstream effector MTOR and of the JAK/STAT target MYC in remission samples compared to the JAK1wt B-ALL cohorts and Ctrls, suggesting that the pathway is switched off in response to venetoclax.